Stock listing
AXSM Stock Price, News, Filings & Events — Axsome Therapeutics, Inc.
Selected listing: AXSM · BX · CHF · CH
This page tracks Axsome Therapeutics, Inc.'s AXSM:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following AXSM:BX. AXSM:BX is the stock-level entry point for investors researching Axsome Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Axsome Therapeutics, Inc. is a public company based in the United States, trading under the ticker AXSM. The company has a market capitalization of approximately $12.4 billion. Axsome focuses on developing innovative therapies for central nervous system disorders.
- Ticker
- AXSM:BX
- Asset type
- Stock
- Market cap
- $10.42B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BX
- Currency
- CHF
Axsome Therapeutics, Inc. AXSM:BX stock context
This page tracks Axsome Therapeutics, Inc.'s AXSM:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following AXSM:BX. AXSM:BX is the stock-level entry point for investors researching Axsome Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Axsome Therapeutics, Inc. is a public company based in the United States, trading under the ticker AXSM. The company has a market capitalization of approximately $12.4 billion. Axsome focuses on developing innovative therapies for central nervous system disorders.
Latest news from Axsome Therapeutics, Inc.
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
July 15, 2026
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
July 14, 2026
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
July 7, 2026
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
June 26, 2026
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
June 18, 2026
Axsome Therapeutics, Inc. earnings calls
Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call
August 10, 2026 · Replay with transcript and chapters
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call
May 4, 2026 · Replay with transcript and chapters
Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call
February 23, 2026 · Replay with transcript and chapters
Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call
November 3, 2025 · Replay with transcript and chapters
Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call
August 4, 2025 · Replay with transcript and chapters
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call
May 6, 2025 · Replay with transcript and chapters
Research Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for AXSM:BX.
Axsome Therapeutics, Inc. company profile
View the public company page for Axsome Therapeutics, Inc. on 6ix.
Axsome Therapeutics, Inc. news
Read company news and market updates connected to Axsome Therapeutics, Inc..
Axsome Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Axsome Therapeutics, Inc..
Alternate listings
AXSM:NASDAQ
US · USD
Alternate listing for Axsome Therapeutics, Inc.; the primary context on this page is AXSM:BX.
A2AA7B:LSX
DE · EUR
Alternate listing for Axsome Therapeutics, Inc.; the primary context on this page is AXSM:BX.
19X:TRADEGATE
DE · EUR
Alternate listing for Axsome Therapeutics, Inc.; the primary context on this page is AXSM:BX.
19X:GETTEX
DE · EUR
Alternate listing for Axsome Therapeutics, Inc.; the primary context on this page is AXSM:BX.
AXSM:BMV
MX · MXN
Alternate listing for Axsome Therapeutics, Inc.; the primary context on this page is AXSM:BX.
0HKF:LSE
GB · USD
Alternate listing for Axsome Therapeutics, Inc.; the primary context on this page is AXSM:BX.
A2AA7B:LS
DE · EUR
Alternate listing for Axsome Therapeutics, Inc.; the primary context on this page is AXSM:BX.
1AXSM:MIL
IT · EUR
Alternate listing for Axsome Therapeutics, Inc.; the primary context on this page is AXSM:BX.
19X:FWB
DE · EUR
Alternate listing for Axsome Therapeutics, Inc.; the primary context on this page is AXSM:BX.
AXSM:BIVA
MX · MXN
Alternate listing for Axsome Therapeutics, Inc.; the primary context on this page is AXSM:BX.
AXSM:BOATS
US · USD
Alternate listing for Axsome Therapeutics, Inc.; the primary context on this page is AXSM:BX.
19X:SWB
DE · EUR
Alternate listing for Axsome Therapeutics, Inc.; the primary context on this page is AXSM:BX.